Skip to main content

Tevogen Inc.

corporate_fare Company Profile

Tevogen Inc.

TVGN·NASDAQ·Life Sciences·CIK 0001860871

We are a clinical-stage specialty immunotherapy company that develops off-the-shelf, precision T cell therapies. Our therapies use CD8+ cytotoxic T lymphocytes (CTLs), also known as killer T cells, which are white blood cells that destroy infected, malignant, or damaged cells. These therapies are designed to treat infectious diseases, cancers, and other disorders. Our precision T cell technology, ExacTcell, is a set of processes and methodologies used to develop, enrich, and expand single human leukocyte antigen (HLA) restricted CTL therapies with proactively selected, precisely defined targets. HLA molecules are proteins important for the immune system to distinguish between "self" and "foreign" cells, and HLA types vary among individuals. ExacTcell therapies are based on carefully selected, naturally occurring CTLs that recognize targets from the body's native T cell receptor pool, differing from genetically engineered T cell therapies. The CD8+ CTLs in ExacTcell-based products target multiple and distinct antigens. These allogeneic therapeutics are pre-manufactured, ready-to-use, and intended for infusion into individuals other than the original donor.

Tevogen Inc. (NASDAQ:TVGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for TVGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for TVGN spans S-3, 10-Q, SCHEDULE 13D/A, 8-K.

Recent high-impact activity:

  • Tevogen Registers 1.03M Lender Shares for Resale as Cash Falls to $144,713
  • Tevogen Q3: $144,713 Cash, Missed Payroll, $28.6M Related-Party Lifeline
  • CEO Ryan Saadi Granted 50 Million Restricted Shares Tied to $1 Billion Revenue Target
  • Tevogen Signs LOI to Explore HRK Healthcare Acquisition, Eyes $100M Revenue
  • Tevogen Ties CEO's 8M Share Grant to $1B Revenue Milestone

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$26.28M
Diluted EPS
-$8.08
Op. Cash Flow
-$12.33M
Free Cash Flow
-$12.39M
Operating Income
-$26.14M
Cash & Equivalents
$0
Debt / Equity
0.00×
Shares Outstanding
4.02M sh
Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020704

Short Interest & Short Volume

4.33 days to cover

FINRA reported short interest of 54,853 shares in TVGN as of the October 30, 2026 settlement, a 1.0% decrease from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 12.5% of TVGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)54,853 shares as of October 30, 2026
Change vs prior period▼ 1.0%
Days to cover4.33 at avg daily volume of 12,670
Daily short volume (FINRA facilities)12.5% of 3,820 shares on November 20, 2026
5-day average short volume26.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for TVGN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-26.

1 shelf registration

Major Investor Registers Shares for Resale · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$5.9
52-week range · as of 2026-11-17 $3.64 – $24.91
Market cap
$405.2M
Volume
9.4K (1.1× avg)
3-mo avg 8.9K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TVGN - Latest Insights

TVGN
Nov 16, 2026, 9:37 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $5.81
Real-time Price: $5.90 info
Change: +$0.090 (+2%) info
Market Cap: $405.205M info
TVGN
Nov 16, 2026, 5:24 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.22
Real-time Price: $5.90 info
Change: -$0.320 (-5%) info
Market Cap: $405.205M info
TVGN
Nov 04, 2026, 4:38 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $5.72
Real-time Price: $5.90 info
Change: +$0.180 (+3%) info
Market Cap: $405.205M info
TVGN
Oct 08, 2026, 2:35 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $5.90 info
Change: -$0.1502 (-2%) info
Market Cap: $405.205M info
TVGN
Sep 16, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.80
Real-time Price: $5.90 info
Change: -$1.90 (-24%) info
Market Cap: $405.205M info
TVGN
Aug 26, 2026, 3:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.69
Real-time Price: $5.90 info
Change: -$0.790 (-12%) info
Market Cap: $405.205M info
TVGN
Aug 14, 2026, 5:16 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.87
Real-time Price: $5.90 info
Change: -$0.970 (-14%) info
Market Cap: $405.205M info
TVGN
Jul 23, 2026, 5:29 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $4.41
Real-time Price: $5.90 info
Change: +$1.49 (+34%) info
Market Cap: $405.205M info
TVGN
Jul 14, 2026, 9:56 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $5.02
Real-time Price: $5.90 info
Change: +$0.880 (+18%) info
Market Cap: $405.205M info
TVGN
Jun 26, 2026, 9:18 AM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $9.54
Real-time Price: $5.90 info
Change: -$3.64 (-38%) info
Market Cap: $405.205M info
TVGN
Jun 12, 2026, 4:59 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $10.47
Real-time Price: $5.90 info
Change: -$4.57 (-44%) info
Market Cap: $405.205M info
TVGN
May 28, 2026, 12:31 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.19
Real-time Price: $5.90 info
Change: -$3.29 (-36%) info
Market Cap: $405.205M info
TVGN
May 21, 2026, 12:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $5.90 info
Change: -$4.22 (-42%) info
Market Cap: $405.205M info
TVGN
May 15, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.95
Real-time Price: $5.90 info
Change: -$2.05 (-26%) info
Market Cap: $405.205M info
TVGN
May 12, 2026, 11:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.13
Real-time Price: $5.90 info
Change: -$1.23 (-17%) info
Market Cap: $405.205M info
TVGN
Apr 22, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.14
Real-time Price: $5.90 info
Change: -$2.24 (-28%) info
Market Cap: $405.205M info
TVGN
Apr 22, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.82
Real-time Price: $5.90 info
Change: -$1.92 (-25%) info
Market Cap: $405.205M info
TVGN
Mar 31, 2026, 5:16 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $4.52
Real-time Price: $5.90 info
Change: +$1.38 (+31%) info
Market Cap: $405.205M info
TVGN
Mar 26, 2026, 12:45 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.15
Real-time Price: $5.90 info
Change: +$0.7526 (+15%) info
Market Cap: $405.205M info
TVGN
Mar 25, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.24
Real-time Price: $5.90 info
Change: +$0.660 (+13%) info
Market Cap: $405.205M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets